Andera Partners

Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Andera Partners co-leads a €67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom

Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases

Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets

Andera Partners co-leads a Series A extension round totalling € 47.75 million for radiopharmaceutical company Ariceum Therapeutics

Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix®

Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure

Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Andera Partners Portfolio Company Mineralys Therapeutics Successfully Completes Upsized $192 Million Nasdaq IPO

Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics, led by Pfizer Ventures, to Advance First-of-its-Kind Neoantigen Creation Approaches

Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension

Andera Partners participates in the $138 Million Series C Financing of Amolyt Pharma led by Sofinnova Partners and co-led by Intermediate Capital Group

Andera Partners raises its largest life sciences fund at €456M, demonstrating the attractiveness of its activity and of the sector

Andera Partners strengthens its Life Sciences team with a new partner

Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension

Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs

Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer

Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients

Andera Partners’ Portfolio Company T-knife Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

Andera Partners strengthens its presence in the DACH region